Novel Mini-Protein Plays a Role in Targeting Cancer Cells : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.
BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.
Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.
The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
have been reported with both types of systems. While early literature focused on fixation and expanded indications, recent studies have evaluated component design and position…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Explore JAAOS peer-reviewed articles covering the expanse of orthopaedic medicine and representing over 39,000 members of the AAOS. Subscribe today!